BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 25320512)

  • 1. Molecular targeting to treat gastric cancer.
    Aoyagi K; Kouhuji K; Kizaki J; Isobe T; Hashimoto K; Shirouzu K
    World J Gastroenterol; 2014 Oct; 20(38):13741-55. PubMed ID: 25320512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting receptor tyrosine kinases in gastric cancer.
    Morishita A; Gong J; Masaki T
    World J Gastroenterol; 2014 Apr; 20(16):4536-45. PubMed ID: 24782606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing strategies for target therapy in gastric cancer.
    Lee SY; Oh SC
    World J Gastroenterol; 2016 Jan; 22(3):1179-89. PubMed ID: 26811656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor a inhibition in gastric cancer.
    Park DJ; Thomas NJ; Yoon C; Yoon SS
    Gastric Cancer; 2015 Jan; 18(1):33-42. PubMed ID: 24993497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapies in gastric cancer and future perspectives.
    Yazici O; Sendur MA; Ozdemir N; Aksoy S
    World J Gastroenterol; 2016 Jan; 22(2):471-89. PubMed ID: 26811601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Companion diagnostics for the targeted therapy of gastric cancer.
    Yoo C; Park YS
    World J Gastroenterol; 2015 Oct; 21(39):10948-55. PubMed ID: 26494953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical management of advanced gastric cancer: the role of new molecular drugs.
    De Vita F; Di Martino N; Fabozzi A; Laterza MM; Ventriglia J; Savastano B; Petrillo A; Gambardella V; Sforza V; Marano L; Auricchio A; Galizia G; Ciardiello F; Orditura M
    World J Gastroenterol; 2014 Oct; 20(40):14537-58. PubMed ID: 25356019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ramucirumab: successfully targeting angiogenesis in gastric cancer.
    Javle M; Smyth EC; Chau I
    Clin Cancer Res; 2014 Dec; 20(23):5875-81. PubMed ID: 25281695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 testing in gastric cancer: An update.
    Abrahao-Machado LF; Scapulatempo-Neto C
    World J Gastroenterol; 2016 May; 22(19):4619-25. PubMed ID: 27217694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and emerging therapies in unresectable and recurrent gastric cancer.
    Jou E; Rajdev L
    World J Gastroenterol; 2016 May; 22(20):4812-23. PubMed ID: 27239108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.
    Roviello G; Ravelli A; Polom K; Petrioli R; Marano L; Marrelli D; Roviello F; Generali D
    Cancer Lett; 2016 Mar; 372(2):187-91. PubMed ID: 26797419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 therapies and gastric cancer: a step forward.
    de Mello RA; Marques AM; Araújo A
    World J Gastroenterol; 2013 Oct; 19(37):6165-9. PubMed ID: 24115812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized medicine in gastric cancer: Where are we and where are we going?
    Jácome AA; Coutinho AK; Lima EM; Andrade AC; Dos Santos JS
    World J Gastroenterol; 2016 Jan; 22(3):1160-71. PubMed ID: 26811654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for antitumor activity of bevacizumab in gastric cancer models.
    Yamashita-Kashima Y; Fujimoto-Ouchi K; Yorozu K; Kurasawa M; Yanagisawa M; Yasuno H; Mori K
    BMC Cancer; 2012 Jan; 12():37. PubMed ID: 22273502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for gastric cancer.
    Smyth EC; Cunningham D
    Curr Treat Options Oncol; 2012 Sep; 13(3):377-89. PubMed ID: 22552927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.
    Joo MK; Park JJ; Chun HJ
    World J Gastroenterol; 2016 May; 22(19):4638-50. PubMed ID: 27217696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials.
    Shan F; Miao R; Xue K; Li Z; Li Z; Bu Z; Wu A; Zhang L; Wu X; Zong X; Wang X; Li S; Ji X; Jia Z; Li Z; Ji J
    Cancer Lett; 2016 Oct; 380(2):598-607. PubMed ID: 26724681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current advances in targeted therapies for metastatic gastric cancer: improving patient care.
    Aguiar PN; Muniz TP; Miranda RR; Tadokoro H; Forones NM; Monteiro ID; Castelo-Branco P; Janjigian YY; De Mello RA
    Future Oncol; 2016 Mar; 12(6):839-54. PubMed ID: 26838766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel targeted agents for gastric cancer.
    Liu L; Wu N; Li J
    J Hematol Oncol; 2012 Jun; 5():31. PubMed ID: 22709792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.